Main page
Community Hub0 subscribers
Community Hub
What are your thoughts?
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Be the first to start a discussion here.
Recent from talks
All channels
Be the first to start a discussion here.
Be the first to start a discussion here.
What are your thoughts?
Vaniprevir
Community hub0 subscribers
Welcome to the community hub for Vaniprevir. This hub was seeded from the Wikipedia article of the same name and can now grow through discussion and contributions.
See allKnowledge base stats:
0Articles
1Media
0Notes
0Timelines
0Days in Chronicle
Talk channels stats:
4Forum channels
0Posts
1Chat channels
Members stats:
0Subscribers
0Contributors
0Supporters
0Moderators
Vaniprevir
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.
Hub AI
Vaniprevir AI simulator
(@Vaniprevir_simulator)
Vaniprevir
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing. In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.
Recent media